Altria (MO) Q1 Earnings Analysis: Adjusted EPS of $1.32 beats consensus by 5.6%. Strong pricing power and growth in on! PLUS confirm resilient fundamentals.
Merck’s (MRK) latest quarterly results saw EPS turn negative due to a massive charge from business development (BD) activities. However, beneath the surface, core product performance and future growth strategies remain more robust than ever, defying initial market concerns. Earnings Summary (Actual vs. Expected) Metric Actual (Current) QoQ Change Vs. Consensus Revenue $ 16.29B -0.7% … Read more
Deep dive into Alphabet’s Q1 2026 earnings. Cloud revenue grew 63% YoY, driven by GenAI infrastructure. Analysis of TPU strategy and Gemini subscription models.
Visa’s Q1 2026 results show strong double-digit growth. Analysis of the new Visa CLI for AI agent payments and expansion of blockchain settlement systems.
Deep dive into AbbVie’s Q1 2026 results. How Skyrizi and Rinvoq are successfully replacing the revenue gap left by Humira’s patent expiration.